Loading…
← CockpitCompetitor Analysis › CGF.AX Challenger LimitedOpen in the cockpit ↗

Challenger LimitedCGF.AXCompetitor analysis, valuation and peers

Australia · AUD·Financials›Life/Health Insurance

Australian retirement-income provider selling annuities and life insurance, plus a funds-management arm.

≈ An Australian annuities specialist like AtheneMomentum leader 92
Mkt cap
$5.26B
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$23.0M
20-day average traded
P/B
1.95×
price to book
ROE
13.3%
delivered
Implied ROE
15.5%
what the price asks
Next earnings
85 days
11 Feb 2027
Close · AUDA$11.95
1D-0.9%
1W-1.9%
1M+3.0%
3M+23.3%
6M+27.8%
YTD+27.0%
1Y+36.7%
ATR %1.6%
52w lowhigh2.9% off high

What Challenger does

Australian retirement-income provider selling annuities and life insurance, plus a funds-management arm.

Takes retirees' lump sums and promises regular payments for a set term or for life, earning the gap between the return on the bonds and property it buys with those funds and the payments it owes. Sales therefore depend on interest rates, and fees from its funds-management arm add a second, steadier line.

In one line: An Australian annuities specialist like Athene.

Products and services

  • Term and lifetime annuities
  • Funds Management (Fidante)
  • Life insurance products

Customers

  • Retirees
  • Financial advisers
  • Institutional investors

Where it sits in the supply chain

  • Retirement income/insurance
  • Annuities (life company)
  • Funds management

What could go right

  • Ageing population/retirement-income demand
  • Interest-rate tailwinds for annuity pricing

What could go wrong

  • Investment/asset-liability mismatch risk
  • Regulatory capital requirement changes

Moat: narrow (regulatory licence, scale, brand). Australia's largest annuity provider under an APRA life-insurance licence, a high barrier to new entrants.

Headquarters: Sydney, Australia · Founded: 1985 · Employees: 577

Named competitors

  • TAL (Dai-ichi Life) private or unlisted
  • AIA Australia private or unlisted
  • Allianz Retire+ private or unlisted
  • Insignia Financial private or unlisted
  • AMP AMP.AX
  • Generation Development Group GDG.AX
  • Perpetual PPT.AX

Challenger at a glance

Size Challenger (CGF.AX) is an Australia Financials company (Life/Health Insurance) with a market value of $5.26B, the 63rd largest of 317 Australia companies the cockpit tracks. Shares closed at A$11.95 on 18 Nov 2026.

Performance Over six months the shares gained 27.8%, against +8.4% for the median peer and +1.2% for the Australia market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue fell 24.9% over the last twelve months (peer median +14.4%); the operating margin is 51.2% (peer median 9.2%).

Valuation It trades at 1.95× book value against a peer median of 3.16× (8th cheapest of 20).

Price implies The share price implies a return on equity of about 15.5%; Challenger delivers 13.3%, so the price asks more than the business earns today.

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026CGF.AX 135Peer median 109
Six months, rebased to 100: Challenger against the median of its 20 peers (local-currency closes).

Challenger financials

Reported figures in AUD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueA$2.32BA$2.21BA$3.03BA$2.95BA$2.25B
Revenue growth—-27%+3%+31%—
Net incomeA$564MA$506MA$192MA$130MA$171M
Free cash flowA$1.90BA$1.90BA$399MA$842MA$1.27B
Capital expenditureA$500,000A$500,000A$200,000A$1.90MA$7.90M
Total debtn/aA$8.46BA$8.27BA$7.13BA$5.89B

Quarterly statements and history in the cockpit →

Challenger competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-10%0%+10%MFSLELFICICILIFESTJSTARHEALTHJXNPRVAVOYAPRI002423MPLBHF7181SDLFCLOV088350HDFCLIFEEQH8795CGF.AX6-month return →1-month return →
Up and to the right = strong over both horizons. Challenger is the large dot.

Fundamentals: return on equity against price-to-book

-100%0%00×200×400×MFSLELFICICILIFESTJSTARHEALTHJXNSDLFHDFCLIFECGF.AXReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Challenger is the large dot.

Capital: ROE delivered against the ROE the price implies

0%20%40%60%80%0%25%50%75%MFSLELFICICILIFESTJSTARHEALTHJXNPRVAVOYAPRI002423MPLBHFCLOVHDFCLIFECRBGCGF.AXROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Challenger is the large dot.

Challenger competitors and peer comparison

Head to head with its named competitors (CGF.AX vs AMP.AX vs GDG.AX vs PPT.AX)
CompanyMarket cap6M returnRevenue growthROEPrice / bookImplied ROE
Challenger CGF.AX$5.26B+28%-25%13%1.95×15.5%
AMP AMP.AX$3.34B+34%-5%5%1.44×14.6%
Generation Development GDG.AX$760M-29%+66%4%1.54×13.6%
Perpetual PPT.AX$1.38B+11%-16%4%1.32×14.1%

How Challenger compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Challenger against its 20 peers (data as of 18 Nov 2026)
MeasureCGF.AXPeer medianRank in peer set
1-month return+3.0%+1.6%9th highest of 21
6-month return+27.8%+8.4%highest of 21
Return on equity13.3%10.4%7th highest of 21
Price / book1.95×3.16×8th cheapest of 20
Trailing P/E17.0×15.5×8th most expensive of 20
ROE the price implies15.5%21.6%8th least demanding of 19
ROE delivered13.3%11.2%7th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Challenger CGF.AXAustralia$5.26B+28%-25%13%1.95×15.5%13.3%
Max Financial Services MFSL.NSIndia$5.25B-12%+18%3%8.53×87.5%3.3%
E-L Financial ELF.TOCanada$4.65B+15%+32%20%0.69×6.5%20.2%
ICICI Life Insurance ICICILIFE.NSIndia$6.90B-15%-8%13%4.72×66.2%12.6%
St. James's Place STJ.LUnited Kingdom$7.12B-10%+164%38%3.55×42.8%38.4%
Star Health & Allied Insurance STARHEALTH.NSIndia$3.53B+8%+21%12%3.16×47.6%11.7%
Jackson Financial Incorporation JXNUnited States$8.76B+20%+34%9%1.11×12.8%9.5%
Privia Health PRVAUnited States$3.14B+6%+19%5%3.85×25.7%4.6%
Voya Financial VOYAUnited States$8.80B+20%0%14%2.32×17.6%14.3%
Primerica PRIUnited States$8.95B+5%+8%31%3.18×23.2%31.1%
COFCO Capital 002423.SZChina$3.08B-7%-31%6%0.83×6.1%5.6%
Medibank Private MPL.AXAustralia$9.81B+8%+9%27%6.03×24.1%26.8%
Brighthouse Financial BHFUnited States$2.42B-33%-9%12%0.48×6.0%12.0%
JAPAN POST INSURANCE 7181.TJapan$11.9B+10%-3%4%0.42×3.2%3.9%
Standard Life SDLF.LUnited Kingdom$12.0B+16%+135%-179%37.44×n/a-179.3%
Clover Health Investments CLOVUnited States$2.21B+16%+54%3%5.31×81.1%3.4%
Hanwha Life 088350.KSSouth Korea$2.09B-33%+20%5%0.23×3.8%4.6%
HDFC Life Insurance HDFCLIFE.NSIndia$13.3B-6%+19%11%6.42×73.8%11.2%
Equitable EQHUnited States$14.2B+26%+11%-183%n/an/an/a
T&d 8795.TJapan$14.4B+22%+1%10%1.41×6.1%9.5%
Corebridge Financial CRBGUnited States$15.1B+26%+10%22%2.44×20.0%21.7%

Questions

Who are Challenger's main competitors?
Named competitors: TAL (Dai-ichi Life) (private or unlisted), AIA Australia (private or unlisted), Allianz Retire+ (private or unlisted), Insignia Financial (private or unlisted), AMP (AMP.AX), Generation Development Group (GDG.AX). The cockpit's measured peer set (industry) also includes Max Financial Services (MFSL.NS), E-L Financial (ELF.TO), ICICI Life Insurance (ICICILIFE.NS), St. James's Place (STJ.L), Star Health & Allied Insurance (STARHEALTH.NS), Jackson Financial Incorporation (JXN).
Is Challenger expensive compared with its peers?
On price / book it trades at 1.95× against a peer median of 3.16×, 8th cheapest of 20 in its peer set. The share price implies a return on equity of about 15.5%; Challenger delivers 13.3%, so the price asks more than the business earns today.
How has Challenger stock performed?
Over six months to 18 Nov 2026 the shares returned +27.8% against +8.4% for the median peer; over one year +36.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.